10-QPeriod: Q2 FY2025

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q2 Ended Jun 30, 2025

Filed August 1, 2025For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) reported its financial results for the quarter and six months ended June 30, 2025. Total revenues for the six months ended June 30, 2025, were $6.704 billion, a slight increase from $6.692 billion in the same period of 2024. Net income for the first six months of 2025 was $2.200 billion, or $20.02 per diluted share, compared to $2.154 billion, or $18.68 per diluted share, in the prior year's period. The company's balance sheet shows total assets of $38.219 billion as of June 30, 2025, and total stockholders' equity of $29.939 billion. The company saw a decrease in net product sales, primarily driven by a significant decline in EYLEA sales, which was partially offset by growth in EYLEA HD and Dupixent. Collaboration revenues, largely from the Sanofi and Bayer partnerships, showed a substantial increase, driven by higher profit shares, particularly from Dupixent. Operating expenses, notably research and development, increased year-over-year, reflecting continued investment in the company's pipeline. Investors should note the ongoing legal proceedings related to EYLEA biosimilar challenges and the company's active share repurchase program, which repurchased approximately $2.122 billion of common stock during the first six months of 2025. The company also declared and paid quarterly dividends.

Financial Highlights

47 data points
Beta

Revenue

$3.68B

Net Income

$1.39B

37.9% Net Margin

EPS (Diluted)

$12.81

Total Assets

$38.22B

Cash & Equivalents

$2.00B

Free Cash Flow

$1.14B

Financial Statements
Beta
Revenue$3.68B
R&D Expenses$1.42B
SG&A Expenses$634.20M
Operating Expenses$2.60B
Operating Income$1.08B
Net Income$1.39B
EPS (Basic)$13.24
EPS (Diluted)$12.81
Shares Outstanding (Basic)105.10M
Shares Outstanding (Diluted)108.60M

Key Highlights

  • 1Total revenues for the six months ended June 30, 2025, increased slightly to $6.704 billion from $6.692 billion in the same period of 2024.
  • 2Net income for the six months ended June 30, 2025, rose to $2.200 billion ($20.02 per diluted share) from $2.154 billion ($18.68 per diluted share) in the prior year.
  • 3Net product sales decreased by $633.3 million for the six months ended June 30, 2025, primarily due to a decline in EYLEA sales, partially offset by growth in EYLEA HD and Dupixent.
  • 4Collaboration revenue increased significantly, driven by higher profit shares from the Sanofi collaboration, notably from Dupixent sales.
  • 5Research and development expenses increased by $300.7 million for the six months ended June 30, 2025, reflecting continued investment in pipeline development.
  • 6The company repurchased approximately $2.122 billion of its common stock during the first six months of 2025.
  • 7Regeneron continues to be involved in significant patent litigation concerning EYLEA and its biosimilars.

Frequently Asked Questions

Regeneron reported total revenues of $6.704 billion for the six months ended June 30, 2025, a slight increase from $6.692 billion in the same period of 2024. This growth was driven by strong collaboration revenues, particularly from its partnership with Sanofi for Dupixent, which offset a decline in net product sales, mainly from EYLEA.

Net product sales for EYLEA decreased significantly by $941.8 million for the six months ended June 30, 2025, compared to the prior year. This decline was attributed to increased competition, market share loss to compounded bevacizumab, and the transition of patients to EYLEA HD, as well as a lower net selling price.

As of June 30, 2025, Regeneron had total assets of $38.219 billion and total stockholders' equity of $29.939 billion. The company maintained substantial liquidity with cash and cash equivalents and marketable securities totaling over $17.5 billion. The company also has a share repurchase program in place, with $2.814 billion remaining authorization as of the reporting date.

Yes, Regeneron is involved in ongoing patent litigation related to EYLEA and its biosimilars in various jurisdictions. The company is actively defending its intellectual property. Additionally, there are ongoing government investigations and legal proceedings related to marketing and business practices, as detailed in Note 12 of the financial statements.